We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Thamanna
Begum
Thamanna.begum@qmul.ac.uk
Dr
Charles
Marshall
Charles.marshall@qmul.ac.uk
Dr
Charles
Marshall
Charles.marshall@qmul.ac.uk
Harshinder
Virdee
harshinder.virdee@nihr.ac.uk
Dr
Charles
Marshall
Charles.marshall@qmul.ac.uk
Organic, including symptomatic, mental disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
We have developed simple hearing tests that measure subtle changes in the brain. Our team has expertise in auditory neuroscience, early detection of dementia , and the diagnostic pathway in NHS memory clinics. It typically takes over three years to get a dementia diagnosis from the time symptoms start. Timely and accurate diagnosis will be vital to ensure access to future treatments that may be able to slow down dementia. However, current diagnostic tests are ‘blunt’ and expensive. Those who are more deprived or from minoritised ethnic groups tend to be diagnosed later and less accurately.
We will evaluate digital hearing tests in a “real-world” setting in memory clinics that serve a diverse and deprived population. We will recruit 500 people attending memory clinics to be evaluated for dementia and 100 healthy controls. We will assess how well our hearing tests identify patients with dementia at initial assessment, and then follow patients for 2 years to establish how well they predict dementia in those who did not receive a diagnosis of dementia initially, allowing some patients with dementia to have earlier access to treatment and support, and some patients without dementia to have earlier reassurance. We will also assess whether our hearing tests have added value when used alongside emerging blood tests for dementia.
The technology is designed to be a cost-effective decision support tool that could be used throughout the NHS as it will require only a computer and internet connection. We will assess the potential cost-effectiveness during the project based on data we acquire about how much it might improve dementia diagnosis.
We will co-produce the research with members of the public and clinicians involved in patient care, working with them to understand the value of the technology to patients, and how best to communicate the outputs in clinical settings.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Validation of investigation /therapeutic procedures;
You can take part if:
You may not be able to take part if:
There will be no exclusion criteria for those attending memory clinics Healthy controls will be excluded if they have significant neurological or psychiatric comorbidities for example a major chronic illness such as multiple sclerosis, Parkinson's disease, schizophrenia or bipolar affective disorder.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Charles
Marshall
Charles.marshall@qmul.ac.uk
Harshinder
Virdee
harshinder.virdee@nihr.ac.uk
Dr
Charles
Marshall
Charles.marshall@qmul.ac.uk
Thamanna
Begum
Thamanna.begum@qmul.ac.uk
Dr
Charles
Marshall
Charles.marshall@qmul.ac.uk
The study is sponsored by Queen Mary University of London and funded by NIHR Central Commissioning Facility (CCF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 60651
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
